AstraZeneca said Sept. 3 that the U.S. Food and Drug Administration has approved Brilinta (ticagrelor) tablets at a new 60 mg dose to be used in patients with a history of heart attack after the first year. Read More »

Cynapsus Therapeutics Inc. on Wednesday announced enrollment of the first patient in the CTH-301 clinical trial. Read More »

Supernus Pharmaceuticals Inc. on Tuesday received its fifth patent covering Oxtellar XR, its novel once-daily, extended-release oxcarbazepine product. Read More »

Innocoll AG on Wednesday announced the first patient has been dosed in its MATRIX-1 (Multisite Assessment of Postoperative Pain Reduction wIth XaraColl) Phase 3 study for the treatment of postoperative pain after open hernioplasty with mesh using XaraColl. Read More »

Heat Biologics Inc. on Tuesday announced it enrolled the first patient in a Phase 1b clinical trial that examines the combination of its HS-110 therapeutic vaccine and the Bristol-Myers Squibb PD-1 inhibitor nivolumab (Opdivo) in non-small cell lung cancer. Read More »

XBiotech, a developer of True Human therapeutic antibodies, announced Tuesday the completion of the first cohort in its Phase 1 of 2 for a clinical study of a novel True Human monoclonal antibody therapy to treat all forms of Staphylococcus aureus infections. Read More »

Adaptimmune Therapeutics, PLC announced Tuesday that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic that targets the NY-ESO-1 cancer antigen in synovial sarcoma patients. Read More »

Merck on Wednesday announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for EMEND (aprepitant) capsules, a substance P/neurokinin 1 receptor antagonist. Read More »

Evotec AG on Wednesday announced that CHDI Foundation Inc. has extended and expanded its collaboration with Evotec through August 2018. Read More »

OncoMed Pharmaceuticals Inc. on Monday announced it has completed patient enrollment in its Phase 2 ALPINE clinical trial of tarextumab for the treatment of pancreatic cancer. Read More »

BeyondSpring Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced Monday its lead compound, Plinabulin, will be presented in two posters at the upcoming 16th World Conference on Lung Cancer (WCLC) in Denver. Read More »

Agile Therapeutics Inc., a women's health specialty pharmaceutical company, on Monday announced active recruitment has closed in its ongoing single-arm, open-label Phase 3 SECURE clinical trial of Twirla, its investigational contraceptive patch. Read More »

Corbus Pharmaceuticals Holdings Inc. on Monday announced that patient enrollment has commenced in the Phase 2 clinical study of its investigational new drug, Resunab, designed for the treatment of diffuse cutaneous systemic sclerosis. Read More »

Titan Pharmaceuticals Inc. on Monday announced the resubmission by Braeburn Pharmaceuticals of a New Drug Application to the U.S. Food and Drug Administration for Probuphine. Read More »

UT Southwestern Medical Center President Daniel K. Podolsky and faculty members recently joined U.S. Reps. Michael C. Burgess (R-TX) and Joe Barton (R-TX) in a roundtable discussion on the 21st Century Cures Act. Read More »

AstraZeneca recently announced a collaboration agreement with Valeant Pharmaceuticals International Inc., under which it will grant an exclusive license for Valeant to develop and commercialize brodalumab. Read More »

BioMarin Pharmaceutical Inc. on Monday announced they will present data in two oral and 19 poster presentations at the Society for the Study of Inborn Errors of Metabolism 2015 Annual Meeting being held today until Sept. 4 in Lyon, France. Read More »

Advaxis Inc. announced on Tuesday that its final clinical data from Stage 1 of the ongoing two-stage Phase 2 study of axalimogene filolisba in patients with persistent or recurrent metastatic carcinoma of the cervix will be presented at the American Gynecological & Obstetrical Society's annual meeting. Read More »

Diamyd Medical announced Monday that it has entered into an exclusive license agreement for using the gluten protein gliadin for the treatment and prevention of type 1 diabetes. Read More »

Gregory MacMichael and Howard B. Johnson named new vice presidents Read More »